alt Hacker NewsNon-small cell lung cancer (NSCLC) treatment has been revolutionized by the checkpoint inhibitors (as well as some other drugs targeting specific mutations).
Non-small cell lung cancer (NSCLC) treatment has been revolutionized by the checkpoint inhibitors (as well as some other drugs targeting specific mutations).
I don't like words like "revolutionized" as they set wrong expectations.
For non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (such as pembrolizumab, nivolumab, or atezolizumab), median overall survival typically ranges from about 10 to 20 months in advanced stages as opposed to 10-12 months for standard chemotherapy treatments.
That's great news especially as they would likely be better tolerated. Bt let's please not call living a handful of months longer as a 'revolution'.